GMPs Send Smaller Supplement Firms Into Contract Manufacturers’ Arms
This article was originally published in The Pink Sheet Daily
FDA enforcement of the good manufacturing practices final rule causes some in the supplement industry to question whether small and medium-sized firms can manufacture in-house successfully. Meanwhile, third-party manufacturers are realizing the benefits of a tighter regulatory environment.
You may also be interested in...
FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.
Baruch jumps to Schiff from Coca-Cola for chief commercial officer role; Perrigo adds Larson for supply chain security; Revo Biolabs’ Balbert retires again; researcher Bushnell leads NCCAM’s new pain program; USANA hires Smidt as R&D VP; Vega ambassadors head to Olympics.
David Einhorn’s questions during Herbalife’s Q1 earnings call sowed market doubt about the firm, whose stock dropped about 20% May 1. But analysts called the panic behind the sell-off “unwarranted” given the firm’s strong Q1 performance and sound fundamentals.